What is Minerva Neurosciences, Inc.'s (NERV) StockRank?

MoatMap's StockRank for Minerva Neurosciences, Inc. (NERV) is 36/100, with a Hold signal. This is a composite score combining Quality (29), Value (46), and Momentum (53) factor ranks across MoatMap's 19,000+ stock universe.

Does Minerva Neurosciences, Inc. have an economic moat?

Minerva Neurosciences, Inc. (NERV) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Minerva Neurosciences, Inc. a buy, hold, or sell?

MoatMap's current signal for Minerva Neurosciences, Inc. (NERV) is Hold, based on a StockRank of 36/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Minerva Neurosciences, Inc. in?

Minerva Neurosciences, Inc. (NERV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NERV

HOLDREMOVE

Minerva Neurosciences, Inc. · Healthcare · United States · $233M · Avg Vol: $567K/d

StockRank

P/E (TTM)

—

ROE

—

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Minerva Neurosciences is a clinical-stage biopharmaceutical company with no commercialized products and negative cash flows. It does not meet any of our quality or compounder criteria.

COMPANY DESCRIPTION

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) disorders, including schizophrenia and insomnia. The company's strategy involves advancing proprietary drug candidates through clinical trials, aiming to address significant unmet needs in neuropsychiatric conditions with potentially differentiated mechanisms of action.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	0	0	0	—
EPS	—	-6.01	-4.61	0.19	-34.67	—
Shares	—	5M	7M	7M	43M	+710.4%
Debt	0	75M	85M	63M	239M	47.0%
Equity	—	-20M	-28M	-26M	-141M	—
Op CF	—	-25M	-15M	-20M	-14M	—
Inv CF	0	-16,326	0	0	0	—
Fin CF	—	-5	20M	0	74M	—

PRICE (1M)-30.6%

SMA 50SMA 200

$4.39

RSI (14)

25.4

52W High

$12.46

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-306.7%0.9

ROE

—N/A

GP/Assets

-9.9%6.8

Op. Margin

0.0%40.6

FCF/Assets

-5.7%34.8

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

17.65x94.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.1x77.3

P/FCF

—N/A

P/B

-0.8x94.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

35%8.8

RS 6M

-1%76.6

SMA 50/200

1.20x89.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+99%71.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$233M

P/E (Forward)

-9.4x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NERV are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NERV	Minerva Neurosciences, Inc.(you)	$233M	36	HOLD
ALXO	ALX Oncology Holdings Inc.	$254M	34	SELL
CDXS	Codexis, Inc.	$250M	32	SELL
ELDN	Eledon Pharmaceuticals, Inc.	$299M	37	HOLD
MGNX	MacroGenics, Inc.	$268M	41	HOLD
FATE	Fate Therapeutics, Inc.	$307M	35	SELL
SRZN	Surrozen, Inc.	$304M	39	HOLD
PRLD	Prelude Therapeutics Incorporated	$313M	34	SELL
IRD	Opus Genetics, Inc.	$342M	39	HOLD
SABS	SAB Biotherapeutics, Inc.	$273M	43	HOLD

Peer medians: ROE -22.4% · P/E 25.1x · Gross margin 44.3%

Minerva Neurosciences, Inc. (NERV) — Stock Score Summary

Minerva Neurosciences, Inc. (NERV) has a MoatMap StockRank of 36/100 based on Quality (29/100), Value (46/100), and Momentum (53/100) factor scores. The current signal is HOLD. Minerva Neurosciences is a clinical-stage biopharmaceutical company with no commercialized products and negative cash flows. It does not meet any of our quality or compounder criteria.

Key Financial Metrics

Price	$4.39
Market Cap	$233M
P/E (Forward)	-9.40
Price/Book	-0.78
Return on Invested Capital	-306.7%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-6M

Minerva Neurosciences, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Minerva Neurosciences, Inc.’s (NERV) StockRank?: MoatMap’s StockRank for Minerva Neurosciences, Inc. (NERV) is 36/100, with a Hold signal. It is a composite of Quality (29), Value (46), and Momentum (53) factor ranks across MoatMap’s 19,000+ stock universe.
Does Minerva Neurosciences, Inc. have an economic moat?: Minerva Neurosciences, Inc. (NERV) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Minerva Neurosciences, Inc. a buy, hold, or sell?: MoatMap’s current signal for Minerva Neurosciences, Inc. (NERV) is Hold, based on a StockRank of 36/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Minerva Neurosciences, Inc. in?: Minerva Neurosciences, Inc. (NERV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).